Loading organizations...
Vivodyne develops an integrated platform that utilizes automated robotics, lab-grown human organ tissue models, and predictive artificial intelligence. This system generates high-fidelity preclinical human data, designed to accelerate drug discovery and optimize therapeutic development by providing more accurate efficacy predictions than traditional methods. The core offering aims to bridge the gap between initial research and clinical trials effectively.
The company was co-founded in 2020 by Andrei Georgescu, who serves as CEO, and Dan Huh. Their foundational insight stemmed from recognizing the urgent need for a more efficient and precise approach to developing treatments for human diseases, departing from conventional animal testing and less predictive in-vitro models. This vision directly addresses the significant time and cost associated with bringing new therapies to market.
Vivodyne targets the pharmaceutical and biotechnology sectors, which continuously seek methods to enhance the speed and reliability of their drug pipelines. The company's long-term vision is to fundamentally transform modern medicine by substantially improving the predictability of therapeutic outcomes, thereby accelerating the availability of novel and effective treatments for patients worldwide.
Vivodyne has raised $78.0M across 2 funding rounds.
Vivodyne has raised $78.0M in total across 2 funding rounds.
Vivodyne has raised $78.0M across 2 funding rounds. Most recently, it raised $40.0M Series A in May 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2025 | $40M Series A | Vinod Khosla | Bison Ventures, Exor Ventures, CS Ventures, Fortius Ventures, Kairos Ventures, Ileana Pirozzi, MBX Capital, US Venture Capital Firm Helena | Announced |
| Nov 22, 2023 | $38M Seed | Alex Morgan | Bison Ventures, CS Ventures, Alex Andrianopoulos, MBX Capital | Announced |
Vivodyne is a biotechnology company developing a platform for preclinical drug discovery using lab-grown human organs, robotics, and AI to generate predictive human data before clinical trials.[1][2][5] It serves biopharma companies by testing thousands of tissues at scale, solving the high failure rate of drugs transitioning from animal models to human trials through ethical, human-relevant alternatives that improve accuracy, speed, and cost-efficiency.[3][5][6] With $38 million in seed funding in 2024 and $40 million in Series A in May 2025, Vivodyne shows strong growth, expanding to a 23,000-square-foot robotic facility in South San Francisco and partnering with leading pharma firms.[6][7]
Vivodyne was founded in 2020 by Dr. Andrei Georgescu, a bioengineering PhD from the University of Pennsylvania, and Associate Professor Dan Huh, emerging from Huh's organ-chip research group.[1][2][4] Georgescu's motivation stemmed from the poor translation between animal studies and human trials; his background includes sending lab-grown tissues to space with NASA and developing DNA synthesis chips.[4] The company launched its platform in 2021, licensing foundational US patents from Penn (US 11,066,633 and US 11,248,199), raised $4 million seed from Kairos Ventures, and earned Fast Company's #1 "Small but Mighty" company spot in 2022 for its automated tissue platform.[3]
Vivodyne rides the convergence of AI-driven biotech, organ-on-chip technology, and automation to address the ~90% preclinical-to-clinical failure rate in drug development.[1][3] Timing aligns with FDA pushes for human-relevant data, rising precision medicine demands, and ethical concerns over animal testing, amplified by post-2020 biotech funding surges.[5][7] Market forces like biopharma's need for faster, cheaper pipelines—amid $2.6B average drug development costs—favor its scalable, predictive platform, influencing the ecosystem by licensing tech to pharma giants and accelerating target discovery in oncology, fibrosis, autoimmune, and infectious diseases.[6][7]
Vivodyne's trajectory points to platform dominance in preclinical testing, with its new South San Francisco facility scaling output for broader biopharma adoption and internal pipelines.[7] Trends like generative AI in biology and regulatory human-data mandates will propel growth, potentially evolving it into a full-stack drug discovery leader or acquisition target. As biotech's "human data before the clinic" pioneer, Vivodyne positions investors and partners to capture value from more successful therapeutics pipelines.[6]
Vivodyne has raised $78.0M in total across 2 funding rounds.
Vivodyne's investors include Vinod Khosla, Bison Ventures, Exor Ventures, CS Ventures, Fortius Ventures, Kairos Ventures, Ileana Pirozzi, MBX Capital, US venture capital firm Helena, Alex Morgan, Alex Andrianopoulos.
